These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

233 related articles for article (PubMed ID: 33309571)

  • 1. Bleeding with vascular endothelial growth factor tyrosine kinase inhibitor: A network meta-analysis.
    Das A; Mahapatra S; Bandyopadhyay D; Samanta S; Chakraborty S; Philpotts LL; Jahangir E; Roy B
    Crit Rev Oncol Hematol; 2021 Jan; 157():103186. PubMed ID: 33309571
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Comparative evaluation of cardiovascular risks among nine FDA-approved VEGFR-TKIs in patients with solid tumors: a Bayesian network analysis of randomized controlled trials.
    Hou W; Ding M; Li X; Zhou X; Zhu Q; Varela-Ramirez A; Yi C
    J Cancer Res Clin Oncol; 2021 Aug; 147(8):2407-2420. PubMed ID: 33725154
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Incidence and risk of hypertension associated with vascular endothelial growth factor receptor tyrosine kinase inhibitors in cancer patients: a comprehensive network meta-analysis of 72 randomized controlled trials involving 30013 patients.
    Liu B; Ding F; Liu Y; Xiong G; Lin T; He D; Zhang Y; Zhang D; Wei G
    Oncotarget; 2016 Oct; 7(41):67661-67673. PubMed ID: 27602778
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Neuropathy with vascular endothelial growth factor receptor tyrosine kinase inhibitors: A meta-analysis.
    Roy B; Das A; Ashish K; Bandyopadhyay D; Maiti A; Chakraborty S; Stone ME; Philpotts LL; Nowak RJ; Patwa HS
    Neurology; 2019 Jul; 93(2):e143-e148. PubMed ID: 31167931
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Risk of gastrointestinal perforation in cancer patients treated with vascular endothelial growth factor receptor tyrosine kinase inhibitors: a systematic review and meta-analysis.
    Qi WX; Sun YJ; Tang LN; Shen Z; Yao Y
    Crit Rev Oncol Hematol; 2014 Mar; 89(3):394-403. PubMed ID: 24182420
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Meta-analysis of randomized controlled trials for the incidence and risk of treatment-related mortality in patients with cancer treated with vascular endothelial growth factor tyrosine kinase inhibitors.
    Schutz FA; Je Y; Richards CJ; Choueiri TK
    J Clin Oncol; 2012 Mar; 30(8):871-7. PubMed ID: 22312105
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Major adverse cardiovascular events of vascular endothelial growth factor tyrosine kinase inhibitors among patients with different malignancy: A systemic review and network meta-analysis.
    Chen YC; Chen JH; Hsieh FI
    J Chin Med Assoc; 2024 Jan; 87(1):48-57. PubMed ID: 37991373
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Analysis of Anti-Angiogenesis-Related Adverse Events Associated with Vascular Endothelial Growth Factor Receptor-Tyrosine Kinase Inhibitors (VEGFR-TKIs) in Patients with Metastatic Renal Cell Carcinoma.
    Lee N; Lee JL; Lee JY
    Target Oncol; 2023 Mar; 18(2):247-255. PubMed ID: 36826462
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Is there truly an increase in risk of cardiovascular and hematological adverse events with vascular endothelial growth factor receptor tyrosine kinase inhibitors?
    Furuya-Kanamori L; Doi SA; Onitilo A; Akhtar S
    Expert Opin Drug Saf; 2020 Feb; 19(2):223-228. PubMed ID: 31698959
    [No Abstract]   [Full Text] [Related]  

  • 10. Safety of combining vascular endothelial growth factor receptor tyrosine-kinase inhibitors with chemotherapy in patients with advanced non-small-cell lung cancer: A PRISMA-compliant meta-analysis.
    Lv WW; Zhang JJ; Zhou XL; Song Z; Wei CM
    Medicine (Baltimore); 2019 Jun; 98(23):e15806. PubMed ID: 31169681
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Risk of hand-foot skin reaction associated with vascular endothelial growth factor-tyrosine kinase inhibitors: A meta-analysis of 57 randomized controlled trials involving 24,956 patients.
    Ding F; Liu B; Wang Y
    J Am Acad Dermatol; 2020 Sep; 83(3):788-796. PubMed ID: 30991119
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Risk of venous thromboembolic events associated with VEGFR-TKIs: a systematic review and meta-analysis.
    Qi WX; Min DL; Shen Z; Sun YJ; Lin F; Tang LN; He AN; Yao Y
    Int J Cancer; 2013 Jun; 132(12):2967-74. PubMed ID: 23225494
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Fatigue associated with newly approved vascular endothelial growth factor receptor tyrosine kinase inhibitors in cancer patients: an up-to-date meta-analysis.
    Li J; Gu J
    Int J Clin Oncol; 2017 Oct; 22(5):807-816. PubMed ID: 28733794
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Incidence and risk of proteinuria associated with newly approved vascular endothelial growth factor receptor tyrosine kinase inhibitors in cancer patients: an up-to-date meta-analysis of randomized controlled trials.
    Zhang W; Feng LJ; Teng F; Li YH; Zhang X; Ran YG
    Expert Rev Clin Pharmacol; 2020 Mar; 13(3):311-320. PubMed ID: 32105149
    [No Abstract]   [Full Text] [Related]  

  • 15. Congestive heart failure risk in cancer patients treated with vascular endothelial growth factor tyrosine kinase inhibitors: a systematic review and meta-analysis of 36 clinical trials.
    Qi WX; Shen Z; Tang LN; Yao Y
    Br J Clin Pharmacol; 2014 Oct; 78(4):748-62. PubMed ID: 24661224
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Incidence and risk of hemorrhagic events with vascular endothelial growth factor receptor tyrosine-kinase inhibitors: an up-to-date meta-analysis of 27 randomized controlled trials.
    Qi WX; Tang LN; Sun YJ; He AN; Lin F; Shen Z; Yao Y
    Ann Oncol; 2013 Dec; 24(12):2943-52. PubMed ID: 23921791
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Tyrosine kinase inhibitors directed against the vascular endothelial growth factor receptor (VEGFR) have distinct cutaneous toxicity profiles: a meta-analysis and review of the literature.
    Massey PR; Okman JS; Wilkerson J; Cowen EW
    Support Care Cancer; 2015 Jun; 23(6):1827-35. PubMed ID: 25471178
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Congestive heart failure with vascular endothelial growth factor receptor tyrosine kinase inhibitors.
    Ghatalia P; Morgan CJ; Je Y; Nguyen PL; Trinh QD; Choueiri TK; Sonpavde G
    Crit Rev Oncol Hematol; 2015 May; 94(2):228-37. PubMed ID: 25577572
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Risk of gastrointestinal events with newly approved (after 2011) vascular endothelial growth factor receptor tyrosine kinase inhibitors in cancer patients: a meta-analysis of randomized controlled trials.
    Li J; Gu J
    Eur J Clin Pharmacol; 2017 Oct; 73(10):1209-1217. PubMed ID: 28710508
    [TBL] [Abstract][Full Text] [Related]  

  • 20. QTc interval prolongation with vascular endothelial growth factor receptor tyrosine kinase inhibitors.
    Ghatalia P; Je Y; Kaymakcalan MD; Sonpavde G; Choueiri TK
    Br J Cancer; 2015 Jan; 112(2):296-305. PubMed ID: 25349964
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.